| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Albutoin's mechanism of action is not fully understood but is believed to be similar to other hydantoin anticonvulsants. It is thought to modulate voltage-gated sodium channels or enhance GABAergic neurotransmission, stabilizing neuronal membranes and reducing neuronal excitability. By reducing abnormal neuronal firing, Albutoin can prevent the spread of seizure activity. Its mechanism of action is a subject of ongoing research.
|
|---|---|
| ln Vitro |
In vitro, Albutoin has been studied for its anticonvulsant activity. Its effects on neuronal excitability can be studied using electrophysiological techniques on cultured neurons. The compound's ability to modulate sodium channels or GABA receptors can be assessed. However, specific in vitro data, such as IC50 or EC50 values, are not detailed in standard product descriptions. Albutoin is a research compound used to study seizure control.
|
| ln Vivo |
In vivo, Albutoin has been investigated for the treatment of grand mal epilepsies. As an anticonvulsant, it is used in research to study seizure control and neuronal excitability. However, specific in vivo protocols and results are not detailed in standard product descriptions. Albutoin is a research compound and is not approved for clinical use.
|
| Enzyme Assay |
In vitro assays for Albutoin measure its effects on neuronal excitability. Electrophysiological techniques, such as patch-clamp, can be used to measure sodium currents or GABA currents in neurons. The compound's ability to modulate these currents is assessed. Receptor binding assays can be used to study its affinity for sodium channels or GABA receptors. These assays confirm the compound's mechanism of action.
|
| Cell Assay |
In vitro cell-based assays for Albutoin are used to study its effects on neuronal function. Neuronal cultures are treated with Albutoin, and the compound's effects on action potential firing are measured using multi-electrode arrays. The compound's ability to reduce neuronal excitability is assessed. These assays confirm the compound's anticonvulsant activity.
|
| Animal Protocol |
In vivo animal experiments for Albutoin are conducted in animal models of epilepsy. In a typical study, Albutoin is administered to animals, and its ability to prevent or reduce seizure activity is assessed using electroencephalography (EEG) or behavioral observation. These studies confirm the in vivo efficacy of Albutoin as an anticonvulsant.
|
| ADME/Pharmacokinetics |
Albutoin has a molecular weight of 212.31 g/mol and a molecular formula of C10H16N2OS. It has a CAS number of 830-89-7. It is a solid compound with a purity of ≥95%. For storage, it is recommended to keep the compound in a cool, dry place. Detailed pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for Albutoin is not provided in standard product descriptions. As an anticonvulsant, it may have side effects similar to other hydantoin derivatives, such as dizziness, drowsiness, and gastrointestinal disturbances. As with all research chemicals, standard laboratory safety precautions should be followed when handling Albutoin. Its use is limited to research applications and it is not intended for human or veterinary use.
|
| References |
|
| Additional Infomation |
Butyryl-CoA is an oxygen- and nitrogen-containing organic compound whose function is related to α-amino acids.
Albutoin is a research compound and is not approved for any clinical or therapeutic use. It is an anticonvulsant agent that is a thiohydantoin derivative. Albutoin is structurally related to hydantoin derivatives and is used in research on seizure control and neuronal excitability. It has been investigated for the treatment of grand mal epilepsies. Albutoin is a valuable research tool for studying epilepsy and anticonvulsant mechanisms. |
| Molecular Formula |
C10H16N2OS
|
|---|---|
| Molecular Weight |
212.31184
|
| Exact Mass |
212.098
|
| CAS # |
830-89-7
|
| PubChem CID |
3032361
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.12g/cm3
|
| Boiling Point |
275.2ºC at 760 mmHg
|
| Flash Point |
120.3ºC
|
| Index of Refraction |
1.558
|
| LogP |
1.088
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
14
|
| Complexity |
263
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)CC1C(=O)N(C(=S)N1)CC=C
|
| InChi Key |
RATGSRSDPNECNO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H16N2OS/c1-4-5-12-9(13)8(6-7(2)3)11-10(12)14/h4,7-8H,1,5-6H2,2-3H3,(H,11,14)
|
| Chemical Name |
5-(2-methylpropyl)-3-prop-2-enyl-2-sulfanylideneimidazolidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1177.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7101 mL | 23.5505 mL | 47.1009 mL | |
| 5 mM | 0.9420 mL | 4.7101 mL | 9.4202 mL | |
| 10 mM | 0.4710 mL | 2.3550 mL | 4.7101 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
